ybbY Antibody

What is YAbS and what types of data does it contain?

YAbS (The Antibody Society's Antibody Therapeutics Database) is a comprehensive resource tracking the development and clinical progress of therapeutic antibodies. The database catalogs detailed information on over 2,900 commercially sponsored investigational antibody candidates that have entered clinical studies since 2000, as well as all approved antibody therapeutics. The open-access portion includes data for over 450 molecules that are approved, in regulatory review, or in late-stage clinical development .

The database contains extensive information on:

• Molecular format and category

• Targeted antigens

• Current development status

• Indications studied

• Clinical development timelines

• Geographical region of company sponsors

• Sequence source information

• Heavy and light chain isotypes

How can researchers access YAbS and what are its primary search functionalities?

Researchers can access YAbS through the online interface at https://db.antibodysociety.org. The database offers multiple search options to accommodate different research needs :

Quick Search Options:

• Target antigen

• Therapeutic area

• Company developing the molecule

Advanced Search Capabilities:

• Molecule name (INN or drug code)

• Molecular characteristics filters

• Clinical development variables

• Date-based filtering for specific timeframes

• Geographical location of developing companies

• Free text search across all columns

The search results are dynamically generated and can be exported for further analysis, making it a versatile tool for various research applications .

What are the inclusion criteria for molecules in the YAbS database?

The YAbS database applies strict inclusion criteria to maintain its focus and utility. For a molecule to be included, it must be :

• A novel, therapeutic, recombinant protein

• Contain at least one antigen-binding site derived from an antibody gene

• Developed or in-licensed by a commercial entity

• Have initial clinical entry on or after January 1, 2000 (with exceptions for approved antibody therapeutics that began clinical studies in the 1980s or 1990s and molecules in late preclinical development)

The database explicitly excludes:

• Biosimilar antibodies

• Antibodies used solely for non-therapeutic purposes

• Polyclonal antibodies from natural sources

• Related molecules lacking an antibody-derived binding site

• Antibody therapeutics in clinical studies sponsored solely by non-commercial organizations

• Antibody therapeutics that entered clinical study before January 1, 2000 (with exceptions for approved therapeutics)

How does YAbS classify antibody therapeutics by molecular characteristics?

YAbS employs a systematic classification scheme for antibody therapeutics based on multiple molecular characteristics :

General Molecular Categories:

• ADCs (Antibody-Drug Conjugates)

• Bi- or multi-specific antibodies

• Immunoconjugates

• Standard monoclonal antibodies

Format Classification:

• General format category (e.g., full length, fragment, appended Ig)

• Heavy and light chain isotypes

• Sequence source information

The database provides schematics of these classification systems (general format, detailed format, and general molecular category) to help researchers understand how antibodies are categorized .

What differentiated features does YAbS offer compared to other antibody databases?

YAbS offers several unique features that distinguish it from other antibody databases :

• Comprehensive timeline tracking: YAbS allows filtering by specific dates (e.g., initiation of clinical study, Phase 2 or 3 start, first approval), enabling analyses of development trends over time.

• Dedicated molecule pages: Each antibody candidate has a dedicated page with key clinical development information and details about companies involved in development.

• Commercial focus: The database specifically tracks commercially sponsored antibody therapeutics, providing insights into industry trends and development strategies.

• Standardized classification: The database employs consistent nomenclature and classification systems for variables such as molecular category, format, and development status.

• Dynamic filtering: The interface allows for complex queries combining multiple parameters, facilitating sophisticated analyses of the antibody therapeutics landscape .

How can YAbS be used to evaluate trends in antibody molecular design over time?

YAbS enables sophisticated analysis of antibody design trends through its date-based filtering capabilities. Researchers can track the evolution of antibody formats, targets, and molecular characteristics over specific time periods to identify emerging patterns and innovations .

For example, researchers can analyze:

• The increasing prevalence of bispecific antibodies and ADCs over traditional monoclonal formats

• Shifts in targeted antigens as new disease pathways are discovered

• Evolution of antibody formats from conventional to engineered structures

• Changes in sequence sources (e.g., fully human versus humanized)

By filtering data based on first-in-human (FIH) study dates, researchers can create chronological analyses of design trends, identifying when specific innovations gained momentum in clinical development .

What insights does YAbS provide about the current clinical-stage antibody therapeutic landscape?

YAbS data reveals several key patterns in the current antibody therapeutics landscape. Analysis of clinical-stage molecules shows :

• Development Status Distribution:

  • 55% of antibodies are in active clinical development

  • Remaining antibodies are either approved, discontinued, or have unknown status

• Clinical Phase Distribution:

  • Approximately 75% of active clinical candidates are in Phase 1 or 1/2

  • Smaller percentages progress to Phase 2 and Phase 3 trials

• Therapeutic Area Focus:

  • 66% of clinical-stage antibodies target cancer indications

  • Remaining antibodies address immunological disorders, infectious diseases, and other therapeutic areas

• Geographic Distribution:

  • Most clinical-stage antibodies originate from companies based in China or the US

  • Other significant contributors include Europe and Japan

These insights help researchers understand the current focus areas, success rates, and geographical distribution of antibody therapeutic development.

How can researchers use YAbS to analyze development timelines for antibody therapeutics?

YAbS provides detailed clinical development timelines that allow researchers to analyze the progression of antibody therapeutics through different clinical phases :

Methodological approach for timeline analysis:

• Use the advanced search to filter molecules by their current development phase

• Apply date filters to identify when molecules entered specific phases

• Calculate average time intervals between clinical milestones

• Compare development timelines across different:

  • Therapeutic areas

  • Molecular formats

  • Target antigens

  • Company regions

Researchers can conduct comparative analyses, such as evaluating whether cancer-targeting antibodies progress through clinical phases faster than those for other indications, or if novel formats like bispecifics have different development timelines than traditional monoclonal antibodies .

What methodologies can researchers employ to evaluate success rates of antibody therapeutics using YAbS?

Methodological approach for success rate analysis:

• Define cohorts based on specific parameters (e.g., time period, format, target)

• Track the progression of each cohort through clinical phases

• Calculate transition probabilities between phases

• Consider potential confounding factors (e.g., strategic vs. efficacy-based discontinuations)

• Compare success rates across different molecular characteristics, indications, or time periods

Several published analyses have used YAbS data to calculate success rates, providing benchmarks for researchers to evaluate the potential of new antibody therapeutics .

How can YAbS facilitate the identification of antibody binding modes and specificity profiles?

While YAbS primarily focuses on clinical and development data, researchers can combine this information with experimental and computational approaches to advance antibody design work :

• Identify successful antibody candidates from YAbS targeting similar antigens

• Analyze their molecular characteristics and binding properties

• Use this information alongside experimental data to inform computational modeling

Recent research has demonstrated that combining high-throughput sequencing data with computational analysis can enable the design of antibodies with specific binding profiles, even for discriminating very similar epitopes. This approach involves identifying different binding modes associated with particular ligands, which can be valuable for designing highly specific antibodies .

Researchers working on antibody specificity can use YAbS to:

• Identify successful candidates targeting related antigens

• Analyze molecular characteristics that may contribute to specificity

• Track the clinical success of antibodies with different specificity profiles

What methodological framework should researchers use when analyzing YAbS data for antibody development patterns?

When analyzing YAbS data for pattern identification, researchers should follow a structured methodological framework :

• Question Formulation:

  • Define specific research questions with clear parameters

  • Identify relevant variables within the database (e.g., molecular formats, targets, timelines)

• Data Extraction and Filtering:

  • Use advanced search functionality to filter data based on relevant parameters

  • Apply temporal filters to establish development trends

  • Export filtered data for detailed analysis

• Analytical Approaches:

  • Conduct descriptive statistical analysis to identify patterns

  • Perform comparative analyses across different variables

  • Apply time-series analysis for developmental trends

  • Consider multivariate analyses to identify correlations between success rates and molecule characteristics

• Validation and Contextualization:

  • Cross-reference findings with published literature

  • Consider market factors and regulatory environments

  • Account for potential data limitations or biases

• Interpretation and Application:

  • Contextualize findings within broader antibody development landscape

  • Develop predictive models for future trends

  • Apply insights to guide research strategy or portfolio decisions

How can researchers effectively combine YAbS data with other computational approaches for antibody engineering?

Researchers can integrate YAbS data with computational approaches to enhance antibody engineering through the following methodology :

• Data Integration Workflow:

  • Extract relevant antibody characteristics from YAbS (format, sequence source, target)

  • Combine with structural data from protein databases

  • Incorporate binding affinity and specificity data from experimental studies

• Computational Analysis Techniques:

  • Sequence-based analysis to identify binding determinants

  • Structural modeling to understand antibody-antigen interactions

  • Machine learning approaches to predict binding properties

• Application to Specificity Engineering:

  • Identify antibodies in YAbS with desired specificity profiles

  • Analyze their molecular characteristics

  • Apply computational models to design new antibodies with enhanced specificity

  • Use experimental validation to confirm computational predictions

Recent research has shown that such integrated approaches can successfully disentangle different binding modes, even for chemically similar ligands, enabling the computational design of antibodies with specific binding profiles .

What statistical methods are most appropriate for analyzing development trends from YAbS data?

Researchers analyzing development trends in YAbS should employ several statistical methods based on the specific questions being addressed :

• For Temporal Trends Analysis:

  • Time series analysis to identify cyclical patterns

  • Regression analysis to quantify trends over time

  • Moving averages to smooth fluctuations and identify underlying patterns

• For Success Rate Analysis:

  • Survival analysis techniques (e.g., Kaplan-Meier curves)

  • Hazard ratios to compare success rates across different categories

  • Multivariate regression to identify factors influencing success

• For Comparative Analysis:

  • Chi-square tests for categorical comparisons

  • ANOVA for comparing means across multiple groups

  • Correlation analyses to identify relationships between variables

• For Predictive Modeling:

  • Machine learning approaches for complex pattern recognition

  • Bayesian methods to incorporate prior knowledge

  • Classification models to predict success based on molecular characteristics

When reporting results, researchers should include confidence intervals, p-values, and effect sizes to facilitate proper interpretation of findings .

How can researchers effectively use YAbS to conduct geographical analysis of antibody development?

YAbS contains data on the geographical distribution of companies developing antibody therapeutics, enabling sophisticated regional analysis :

Methodological approach for geographical analysis:

• Data Extraction and Classification:

  • Filter antibody candidates by company region (available in advanced search)

  • Classify by development stage, therapeutic area, and molecular characteristics

  • Extract temporal data to analyze regional trends over time

• Comparative Analysis Framework:

  • Compare antibody formats and targets across different regions

  • Analyze success rates by geographical region

  • Evaluate differences in therapeutic focus areas across regions

• Visualization Techniques:

  • Create geographical heat maps of antibody development activity

  • Generate time-series visualizations of regional development trends

  • Develop comparative charts of molecular characteristics by region

• Contextual Analysis:

  • Correlate findings with regional regulatory environments

  • Consider local disease prevalence and healthcare priorities

  • Analyze regional scientific and technological capabilities

This approach reveals significant regional patterns, such as the current concentration of clinical-stage antibody development in China and the US, as well as differences in therapeutic focus areas across regions .

What are the limitations of YAbS data and how should researchers account for them in their analyses?

When working with YAbS data, researchers should be aware of several limitations and incorporate appropriate methodological adjustments :

Key Limitations:

• Information Gaps:

  • Some early-stage development information may not be fully disclosed by companies

  • Certain molecular details might be proprietary or incompletely reported

• Selection Criteria Effects:

  • The database's inclusion criteria may exclude certain categories of antibody-related molecules

  • Focus on commercially sponsored molecules excludes purely academic research

• Reporting Delays:

  • Lag time between clinical events and their inclusion in the database

  • Variation in disclosure practices across companies and regions

Methodological Adjustments:

• For Information Gaps:

  • Clearly state data limitations in research reports

  • Implement sensitivity analyses to assess the impact of missing data

  • Consider supplementary data sources for validation

• For Selection Effects:

  • Explicitly define the scope of analysis based on database coverage

  • Avoid overgeneralizing findings to antibody types not included in the database

• For Reporting Delays:

  • Incorporate time buffers in temporal analyses

  • Use date ranges rather than specific points for trend analysis

  • Regularly update analyses as new information becomes available

Despite these limitations, YAbS remains a robust resource for antibody therapeutics research when these methodological considerations are properly addressed .

How can YAbS data inform strategies for developing next-generation antibody therapeutics?

YAbS data provides valuable insights that can guide the development of next-generation antibody therapeutics through several strategic approaches :

• Target Selection Strategy:

  • Analyze patterns of successful targets across therapeutic areas

  • Identify under-explored targets with potential therapeutic value

  • Evaluate target saturation in specific disease areas

• Format Optimization Framework:

  • Track the clinical success rates of different antibody formats

  • Analyze relationships between molecular characteristics and clinical outcomes

  • Identify format innovations that improve efficacy or reduce adverse events

• Development Strategy Refinement:

  • Analyze phase transition timelines to optimize development pathways

  • Identify successful strategies for accelerated approval

  • Compare development approaches across different therapeutic areas

• Risk Assessment Methodology:

  • Calculate success probabilities based on molecular and clinical characteristics

  • Identify high-risk and high-reward approaches

  • Develop quantitative models for portfolio optimization

By analyzing historical patterns and current trends in the database, researchers can make informed decisions about antibody design, target selection, and development strategies that have higher probabilities of clinical success .

What methodological approaches can researchers use to identify gaps in the current antibody therapeutics landscape?

Researchers can employ several methodological approaches using YAbS data to identify opportunities in the antibody therapeutics landscape :

• Target Distribution Analysis:

  • Map current antibody targets against known disease-associated proteins

  • Identify therapeutic areas with limited antibody development

  • Quantify target redundancy across the development pipeline

• Unmet Need Assessment:

  • Compare antibody development activity against disease burden metrics

  • Identify therapeutic areas with high unmet needs but limited antibody development

  • Analyze discontinuation patterns to identify challenging targets

• Innovation Gap Analysis:

  • Assess the distribution of conventional versus novel antibody formats

  • Identify therapeutic areas dominated by conventional approaches

  • Evaluate the application of novel formats across different disease contexts

• Comparative Success Analysis:

  • Analyze success rates across different therapeutic areas

  • Identify areas where antibody approaches have been underutilized

  • Compare success rates of different molecular approaches for similar targets

This systematic analysis can reveal opportunities for innovation in terms of novel targets, unexplored therapeutic areas, or the application of advanced antibody formats to address challenging disease mechanisms .

How might researchers use YAbS data to predict emerging trends in antibody design and engineering?

YAbS data can be leveraged to predict emerging trends in antibody design through several predictive methodologies :

• Temporal Pattern Analysis:

  • Track the evolution of antibody formats over time

  • Identify acceleration points where novel formats gained momentum

  • Project trend lines to forecast future development patterns

• Success Rate Modeling:

  • Calculate historical success rates for different antibody formats

  • Identify characteristics associated with higher clinical success

  • Develop predictive models incorporating multiple variables

• Technology Diffusion Analysis:

  • Track how novel antibody technologies spread across different therapeutic areas

  • Identify early adopters and innovation patterns

  • Model the diffusion of successful innovations across the industry

• Convergence Point Identification:

  • Analyze where multiple technological trends intersect

  • Identify synergistic combinations of antibody technologies

  • Predict emerging hybridized approaches

Recent work combining experimental data with computational modeling demonstrates how researchers can go beyond the historical data to design antibodies with specific binding profiles, suggesting that predictive approaches will become increasingly important in antibody engineering .

What methodological framework should researchers use to analyze YAbS data for therapeutic area expansion?

Researchers can implement a structured methodological framework to identify opportunities for expanding antibody applications into new therapeutic areas :

• Cross-therapeutic Analysis Protocol:

  • Map successful antibody mechanisms across different therapeutic areas

  • Identify mechanistic similarities between disease pathways

  • Analyze targets with potential applications across multiple indications

• Mechanism Translation Framework:

  • Identify antibody mechanisms successful in one therapeutic area

  • Evaluate biological relevance to other disease contexts

  • Assess the translational potential of mechanisms across therapeutic boundaries

• Format-Indication Match Analysis:

  • Analyze which antibody formats perform best in specific therapeutic contexts

  • Identify format characteristics suited to different physiological environments

  • Evaluate format-specific barriers to therapeutic area expansion

• Regulatory Pathway Comparison:

  • Analyze development timelines across therapeutic areas

  • Identify regulatory factors affecting therapeutic area expansion

  • Develop strategies for efficient cross-indication development

This framework helps researchers systematically evaluate opportunities for repositioning antibody approaches or developing new applications based on successful mechanisms in other therapeutic contexts .

How can integration of YAbS with other computational tools enhance antibody engineering and design?

The integration of YAbS data with complementary computational tools creates powerful opportunities for advanced antibody engineering :

• Integrated Data Workflow:

  • Combine YAbS clinical development data with:

    • Structural databases (e.g., PDB)

    • Binding affinity datasets

    • Next-generation sequencing data

    • Computational prediction tools

• Multi-modal Analysis Approaches:

  • Correlate clinical success with molecular and structural characteristics

  • Identify structure-function relationships through integrated analysis

  • Apply machine learning to identify success-associated patterns

• Design-Test-Learn Cycle Implementation:

  • Use YAbS to identify successful antibody characteristics

  • Apply computational tools to design candidates with these characteristics

  • Validate designs experimentally

  • Feed results back into predictive models

• Specificity Engineering Methodology:

  • Analyze binding modes and specificity profiles from successful antibodies

  • Apply computational modeling to design antibodies with enhanced specificity

  • Use high-throughput experimental methods to validate predictions

  • Iterate design based on experimental feedback

Recent research demonstrates that combining experimental phage display data with computational modeling can successfully disentangle different binding modes, enabling the design of antibodies with specific binding profiles even for chemically similar ligands. This integrated approach represents the future direction of antibody engineering, where databases like YAbS provide the foundational knowledge to guide advanced computational design strategies .

Current Distribution of Antibody Therapeutics by Development Stage (As of January 2025)

Data derived from analysis of YAbS database contents

Distribution of Antibody Therapeutics in Active Clinical Development by Phase

Based on analysis of YAbS data for actively developing antibody therapeutics

Distribution of Antibody Therapeutics by Therapeutic Area

Data extracted from YAbS database analysis of clinical-stage therapeutics

Geographical Distribution of Antibody Therapeutic Development

Based on company region data from YAbS for clinical-stage antibodies

Key Variables Available for Analysis in YAbS Database